BioDelivery Sciences International Announces ELYXYB is Now Available in the US for the Acute Treatment of Migraine
BioDelivery Sciences International, Inc. recently announced the US commercial launch and availability of ELYXYB (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.
“ELYXYB represents a significant innovation in the rapidly growing migraine market and our initial entry into the Neurology space, which is complementary to our current sales and marketing efforts,” said Jeff Bailey, CEO of BDSI. “We have been diligently preparing for this launch and are ready and excited to deliver this important acute treatment option to patients who are experiencing the life-altering effects of migraine disease.”
Migraine is a debilitating condition for almost 40 million people in the US. Many patients with migraine are searching for acute treatments that provide relief quickly and conveniently, without interfering with daily quality of life.
“Millions of patients are cycling through the multitude of current migraine treatments, searching for what will work quickly and what will last, whenever a migraine strikes,” said Peter McAllister, MD, Director of the New England Center for Neurology and Headache. “Physicians are looking for new treatment options that are effective, with favorable safety and tolerability, and less contraindications. ELYXYB is uniquely formulated to provide fast-acting, long-lasting relief in a convenient, ready-to-use oral solution, and will be a go-to option for many of my patients with migraine.”
ELYXYB is an oral solution of celecoxib, formulated using a self-microemulsifying drug delivery system (SMEDDS) that improves solubility and bioavailability leading to better absorption. This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a higher dose of the conventional oral capsule, which doesn’t have the rapid onset of action that migraine patients need. ELYXYB comes in a small, single-dose bottle that does not require premixing, shaking, or measuring, making it convenient for patients to take immediately upon the onset of a migraine attack.
BDSI is committed to ensuring access to appropriate patients who are prescribed ELYXYB. The ELYXYB Passport Program provides access support and resources to both healthcare providers and patients, including a co-pay savings program. For more information on ELYXYB and the ELYXYB Passport Program visit ELYXYB.com. ELYXYB is protected by six Orange Book-listed method-of-use patents that expire in 2036 as well as by New Product Exclusivity expiring in May 2023.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated products that address serious and debilitating conditions, including chronic pain, migraine, and opioid-induced constipation.
Total Page Views: 856
